[{"address1": "Bahnhofstrasse 7", "city": "Zug", "zip": "6300", "country": "Switzerland", "phone": "41 41 711 9325", "website": "https://oculis.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. Riad  Sherif M.B.A., M.D.", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sylvia  Cheung", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramin  Tadayoni M.D., Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Virginia R. Dean", "age": 56, "title": "Chief Human Resources Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bastian  Dehmel M.D.", "age": 52, "title": "Chief Development Officer", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. P\u00e1ll Ragnar J\u00f3hannesson", "age": 41, "title": "Chief Business Officer", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rebecca  Weil", "title": "Chief Commercial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Snehal  Shah Pharm.D.", "title": "President of Research & Development", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 12.0, "open": 12.0, "dayLow": 11.97, "dayHigh": 12.002, "regularMarketPreviousClose": 12.0, "regularMarketOpen": 12.0, "regularMarketDayLow": 11.97, "regularMarketDayHigh": 12.002, "beta": 0.085, "forwardPE": -5.123932, "volume": 28714, "regularMarketVolume": 28714, "averageVolume": 15972, "averageVolume10days": 28730, "averageDailyVolume10Day": 28730, "bid": 11.91, "ask": 12.03, "bidSize": 100, "askSize": 100, "marketCap": 500526144, "fiftyTwoWeekLow": 9.05, "fiftyTwoWeekHigh": 14.465, "priceToSalesTrailing12Months": 574.65686, "fiftyDayAverage": 11.69048, "twoHundredDayAverage": 11.671425, "currency": "USD", "enterpriseValue": 383942080, "floatShares": 39547823, "sharesOutstanding": 41745300, "sharesShort": 20792, "sharesShortPriorMonth": 21046, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0005, "heldPercentInsiders": 0.07226, "heldPercentInstitutions": 0.32588002, "shortRatio": 2.13, "shortPercentOfFloat": 0.00059999997, "bookValue": 2.703, "priceToBook": 4.435812, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -66842000, "trailingEps": -1.64, "forwardEps": -2.34, "pegRatio": -0.14, "enterpriseToRevenue": 440.806, "enterpriseToEbitda": -6.11, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCS", "underlyingSymbol": "OCS", "shortName": "Oculis Holding AG", "longName": "Oculis Holding AG", "firstTradeDateEpochUtc": 1621344600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "48d18c2f-9253-3694-a9c9-9afae38b7b9c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.99, "targetHighPrice": 36.66, "targetLowPrice": 19.81, "targetMeanPrice": 28.45, "targetMedianPrice": 29.73, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 117922000, "totalCashPerShare": 2.825, "ebitda": -62840000, "totalDebt": 1338000, "quickRatio": 5.089, "currentRatio": 5.274, "totalRevenue": 871000, "debtToEquity": 1.186, "revenuePerShare": 0.023, "returnOnAssets": -0.28766, "returnOnEquity": -0.58118, "freeCashflow": -25163376, "operatingCashflow": -51706000, "revenueGrowth": -0.02, "operatingMargins": -91.775505, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]